By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...

Eli Lilly's ( LLY) weight-loss drug, Mounjaro, has become the best-selling medication in India by value as of October, surpassing GSK's ( GSK) antibiotic, Augmentin, a Reuters report said.

Eli Lilly's blockbuster obesity ​drug Mounjaro became India's ‌top-selling drug by value for the ‌month of October with sales ...

Eli Lilly's Mounjaro tops India's drug sales in October, surpassing GSK's Augmentin with ₹100 crore in revenue.

Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, ...

Eli Lilly recorded ₹1 billion in Mounjaro sales in October, compared to Augmentin’s ₹800 million ・Since its March 2025 launch ...

COPENHAGEN (Reuters) -Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to ...

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Mounjaro, the breakthrough obesity and diabetes drug from Eli Lilly and Company, has become India’s highest-selling pharmaceutical brand in October, according to fresh data from market intelligence ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...